FGID and fatigue

Almost 2/3 of patients with inflammatory bowel disease (IBD), who initiate biologic therapy (infliximab, adalimumab, vedolizumab, or ustekinumab) continue to experience persistent fatigue up to 1 year later. Ongoing inflammation was thought to be the main cause of IBD related fatigue, however research now suggests that gut dysbiosis and a less diverse microbiome may be the prevailing factor.  According to